Genetic variation of the CYP17 and susceptibility to endometrial cancer: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 8, 2013, Pages 5085-5091

  Xu, Jun ^a   Lin, Xiao ^a   Zhu, Haoping ^a   Zhang, Zhiling ^a   Yang, Baohua ^a  

^a The Central Hospital of Minhang District   (China)

Author keywords

CYP17; Endometrial cancer; Meta analysis; Polymorphism

Indexed keywords

CYTOCHROME P450 17; CYTOSINE; MESSENGER RNA; TYROSINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CYP17 GENE; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ETHNICITY; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; PUBLISHING; RANDOMIZATION; RECESSIVE GENE; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EID: 84881120461     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2609-0     Document Type: Article

References (34)

1. Smith RA, Cokkinides V, Brawley OW (2009) Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59:27-41
2. Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237-246
3. Flototto T, Djahansouzi S, Glaser M, et al. (2001) Hormones and hormone antagonists: mechanism of action in carcinogenesis of endometrial and breast cancer. Horm Metab Res 33:451-457
4. Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960
5. Sharp L, Cardy AH, Cotton SC, Little J (2004) CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A HuGE review. Am J Epidemiol 160:729-740
6. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587
7. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065
8. Holm K, Melum E, Franke A, Karlsen TH (2010) SNPexp - a web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinform 11:600
9. International HapMap Consortium (2003) The International HapMap Project. Nature 426:789-796
10. Stranger BE, Forrest MS, Dunning M, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315:848-853
11. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
13. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
14. Haiman CA, Hankinson SE, Colditz GA, et al. (2001) A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61:3955-3960
15. McKean-Cowdin R, Feigelson HS, Pike MC, et al. (2001) Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 61:848-849
16. Berstein LM, Imyanitov EN, Kovalevskij AJ, et al. (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207:191-196
17. Aban M, Arslan M, Tok E, et al. (2006) CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. Int J Gynecol Cancer 16(suppl 1):448-451
18. Szyllo K, Smolarz B, Romanowicz-Makowska H, Lewy J, Kulig B (2006) The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endometrial cancer. J Exp Clin Cancer Res 25:411-416
19. Chen C, Doherty JA, Weiss NS (2006) Polymorphisms in CYP17 and CYP19, unopposed estrogen use, body mass index, full-term pregnancy, and endometrial cancer risk. Proc Am Assoc Cancer Res 47:1269
20. Li R, Lu AN, Liao YM (2007) Correlation between gene polymorphism CYP17 and endometrial cancer. Zhongguo Ji Ceng Yi Yao 14:67-68 (in Chinese)
21. Gao J, Xiang YB, Xu WH, Cheng JR, Cai QY, Shu XO, Gao YT (2007) A case-control study on genetic polymorphism of CYP17 MspA(1)I and its association with endometrial cancer risk. Zhonghua Zhong Liu Za Zhi 29:266-269 (in Chinese)
22. Liu J, Yang YS, Qu X, Li H, Zhong YH (2007) Relation among single nucleotide polymorphism in estrogen metabolizing genes CYP17, COMT and endometrial adenocarcinoma risk. Shandong Daxue Xue Bao 45:18-21 (in Chinese)
23. Gaudet MM, Lacey JV Jr, Lissowska J, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M (2008) Genetic variation in CYP17 and endometrial cancer risk. Hum Genet 123:155-162
24. Olson SH, Orlow I, Bayuga S, et al. (2008) Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 19:955-963
25. Hirata H, Hinoda Y, Okayama N, et al. (2008) CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112:1964-1973
26. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ (2010) Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol 34:328-337
27. Spurdle AB, Thompson DJ, Ahmed S, et al. (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43:451-454
28. Chen Y, Saini S, Zaman MS, Hirata H, Shahryari V, Deng G, Dahiya R (2011) Cytochrome P450 17 (CYP17) is involved in endometrial cancinogenesis through apoptosis and invasion pathways. Mol Carcinog 50:16-23
29. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, et al. (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825-2828
30. Jernström H, Vesprini D, Bradlow HL, Narod SA (2001) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 93:554-555
31. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96:936-945
32. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531-1543
33. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M, Mittal KR, Raju U, Banerjee S, Toniolo P (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84:975-981
34. Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, Kuligina E, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG (2002) CYP17 genetic polymorphism in endometrial cancer: Are only steroids involved? Cancer Lett 180:47-53